Affordable Access

Publisher Website

Enhancement of endocannabinoid signaling and the pharmacotherapy of depression

Authors
Journal
Pharmacological Research
1043-6618
Publisher
Elsevier
Publication Date
Volume
56
Issue
5
Identifiers
DOI: 10.1016/j.phrs.2007.09.003
Keywords
  • Endocannabinoid
  • Anandamide
  • 2-Ag
  • Depression
Disciplines
  • Medicine

Abstract

Abstract Cannabinoids are well known modulators of mood and emotional behavior. Current research supports a role for endocannabinoid signaling in the treatment of depression. Changes in levels of the cannabinoid CB 1 receptor or the endogenous CB 1 receptor ligands, anandamide and 2-AG, are observed both in humans suffering from depression and in animal models of depression, and experimental manipulation of CB 1 receptor signaling has also been shown to affect emotional reactivity in rodents. Importantly, inhibitors of anandamide inactivation have demonstrated efficacy in enhancing stress-coping and mood-related behavior. This article will review these areas of research, highlighting the potential of endocannabinoid metabolism modulators as therapeutics for the treatment of depression.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Enhancement of endocannabinoid signaling and the p...

on Pharmacological research November 2007

Role of endocannabinoid signaling in anxiety and d...

on Current topics in behavioral n... 2009

Enhancement of endocannabinoid signaling protects...

on Toxicology and Applied Pharmac... Aug 01, 2015
More articles like this..